

**Meeting Assurance Report
to the Board of Directors**

Name of Committee / Group	Research and Innovation Committee
Date of Meeting	16 December 2024
Chair	Dean Royles, Non-Executive Director and Committee Chair
Lead Officer	David Black, Chief Medical Officer (Development)
Meeting Administrator	Moyosore Orioye, Business Manager, Chief Executive's Office

Purpose

The purpose of this report is to provide in summary an update on the key discussions and outcomes of the above meeting.

Agenda items covered at the meeting

The agenda included the following items:

- Research and Innovation Strategy and Implementation Plan Update (WB)
- Research and Innovation Performance and Insights (WB)
- Academic Health Science Partnership Update (DB)
- 360 Assurance Directorate Research – Planning and Performance (WB)
- Research Executive Committee and Innovation Executive Committee Meeting Assurance Reports from the meetings held on 10 December 2024 and 9 December 2024

Matters to highlight

Specific areas to highlight are as follows:

- Received an update on progress on the research and innovation strategy implementation plan and noted that consultation had been completed including sessions with MBB and Research and Innovation Leads
- The consultation process highlighted a contrast between the frustration colleagues felt along with the vital and essential nature of research and innovation to the success of the organisation.
- The committee agreed to combining the 360 assurance actions with implementation plan actions into one master document
- The committee agreed that research and innovation success measures should be integrated into the Trust business planning processes.
- Recognised that the actions being taken would have a positive impact on research and innovation culture but agreed that this should be kept under review with a view to further interventions if required
- Noted that a proposal on the allocation of research and innovation funding would be presented to TEG with an update to the next meeting of the committee
- Recognised the importance of aligning actions on developing the research and innovation workforce with the People Committee

- Received the performance and insight report and noted actions in respect of pharmacy and recognised the need for improved governance to ensure that research trials unlikely to meet set up timescales are not approved
- Welcomed the measure on recruitment to trials by directorate as an important improvement driver
- Received and update on innovation developments and progress and agreed that this should be integrated more into the meeting agenda and that it should include updates on ROI and spread.
- Received a progress update on the development of an Academic Health Partnership and asked that actions and partner discussions be expedited with a view to presentation of a timeline for implementation at the next meeting of the committee.
- Received assurance reports from the research and the innovation executive committees.

Documents approved were:

N/A

New significant issues / concerns escalated including proposals on the next steps to address this

New areas which the Committee / Group wishes to escalate as potential areas of non-compliance, that need addressing urgently or escalating:

None.

Implications

Aim of the STHFT Corporate Strategy		✓ Tick as appropriate
1	Deliver the Best Clinical Outcomes	✓
2	Provide Patient Centred Services	✓
3	Employ Caring and Cared for Staff	✓
4	Spend Public Money Wisely	✓
5	Create a Sustainable Organisation	✓
6	Deliver Excellent Research, Education and Innovation	✓

Recommendations

The Board is asked to **NOTE** the update provided and respond to any specific points raised within the report.